EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology

SALT LAKE CITY and TORONTO, July 29, 2014 /PRNewswire via COMTEX/ EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces expansion of its pharmaceutical development implementing its sub-micron platform technology. The company s new development direction includes large molecule drugs that will address indications in diabetes and the overall metabolic syndrome. The company s sub-micron technology allows for development of harmonized formulations and better absorption. To date, the company has demonstrated initial proven success of the technology with Lorazepam in animals. In its application for specific pharmaceutical molecules the company has been able to achieve positive results with drugs that are currently injected. The company continues the development of its transmucosal Lorazepam Spray
http://bit.ly/1mYOhK7